Alex B Blair1, Vincent P Groot1, Georgios Gemenetzis1, Jishu Wei1, John L Cameron2, Matthew J Weiss2, Michael Goggins3, Christopher L Wolfgang4, Jun Yu1, Jin He5. 1. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. 2. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. 3. Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. 4. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. 5. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: jhe11@jhmi.edu.
Abstract
BACKGROUND: The outcomes of sporadic pancreatic ductal adenocarcinoma (PDAC) patients with germline mutations of BRCA1/BRCA2 remains unclear. The prognostic significance of BRCA1/BRCA2 mutations on survival is not well established. STUDY DESIGN: We performed targeted next-generation sequencing (NGS) to identify BRCA1/BRCA2 germline mutations in resected sporadic PDAC cases from 2000 to 2015. Germline BRCA mutation carriers were matched by age and tumor location to those with BRCA1/BRCA2 wild-type genes from our institutional database. Demographics, clinicopathologic features, overall survival (OS), and disease-free survival (DFS) were abstracted from medical records and compared between the 2 cohorts. RESULTS: Twenty-two patients with sporadic cancer and BRCA1 (n = 4) or BRCA2 (n = 18) germline mutations and 105 wild-type patients were identified for this case-control study. The BRCA1/BRCA2 mutations were associated with inferior median OS (20.2 vs 27.8 months, p = 0.034) and DFS (8.4 vs 16.7 months, p < 0.001) when compared with the matched wild-type controls. On multivariable analyses, a BRCA1/BRCA2 mutation (hazard ratio [HR] 2.10, p < 0.001), positive margin status (HR 1.72, p = 0.021), and lack of adjuvant therapy (HR 2.38, p < 0.001), were all independently associated with worse survival. Within the BRCA1/BRCA2 mutated group, having had platinum-based adjuvant chemotherapy (n = 10) was associated with better survival than alternative chemotherapy (n = 8) or no adjuvant therapy (n = 4) (31.0 vs 17.8 vs 9.3 months, respectively, p < 0.001). CONCLUSIONS: Carriers of BRCA1/BRCA2 mutation with sporadic PDAC had a worse survival after pancreatectomy than their BRCA wild-type counterparts. However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients.
BACKGROUND: The outcomes of sporadic pancreatic ductal adenocarcinoma (PDAC) patients with germline mutations of BRCA1/BRCA2 remains unclear. The prognostic significance of BRCA1/BRCA2 mutations on survival is not well established. STUDY DESIGN: We performed targeted next-generation sequencing (NGS) to identify BRCA1/BRCA2 germline mutations in resected sporadic PDAC cases from 2000 to 2015. Germline BRCA mutation carriers were matched by age and tumor location to those with BRCA1/BRCA2 wild-type genes from our institutional database. Demographics, clinicopathologic features, overall survival (OS), and disease-free survival (DFS) were abstracted from medical records and compared between the 2 cohorts. RESULTS: Twenty-two patients with sporadic cancer and BRCA1 (n = 4) or BRCA2 (n = 18) germline mutations and 105 wild-type patients were identified for this case-control study. The BRCA1/BRCA2 mutations were associated with inferior median OS (20.2 vs 27.8 months, p = 0.034) and DFS (8.4 vs 16.7 months, p < 0.001) when compared with the matched wild-type controls. On multivariable analyses, a BRCA1/BRCA2 mutation (hazard ratio [HR] 2.10, p < 0.001), positive margin status (HR 1.72, p = 0.021), and lack of adjuvant therapy (HR 2.38, p < 0.001), were all independently associated with worse survival. Within the BRCA1/BRCA2 mutated group, having had platinum-based adjuvant chemotherapy (n = 10) was associated with better survival than alternative chemotherapy (n = 8) or no adjuvant therapy (n = 4) (31.0 vs 17.8 vs 9.3 months, respectively, p < 0.001). CONCLUSIONS: Carriers of BRCA1/BRCA2 mutation with sporadic PDAC had a worse survival after pancreatectomy than their BRCA wild-type counterparts. However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1/BRCA2 mutations, with survival differences no longer appreciated with wild-type patients.
Authors: Jorg Kleeff; Murray Korc; Minoti Apte; Carlo La Vecchia; Colin D Johnson; Andrew V Biankin; Rachel E Neale; Margaret Tempero; David A Tuveson; Ralph H Hruban; John P Neoptolemos Journal: Nat Rev Dis Primers Date: 2016-04-21 Impact factor: 52.329
Authors: Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban Journal: CA Cancer J Clin Date: 2013-07-15 Impact factor: 508.702
Authors: Fergus J Couch; Michele R Johnson; Kari G Rabe; Kieran Brune; Mariza de Andrade; Michael Goggins; Heidi Rothenmund; Steven Gallinger; Alison Klein; Gloria M Petersen; Ralph H Hruban Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-02 Impact factor: 4.254
Authors: Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Stephan A Hahn; Bill Greenhalf; Ian Ellis; Mercedes Sina-Frey; Harald Rieder; Birgit Korte; Berthold Gerdes; Ralf Kress; Andreas Ziegler; John A Raeburn; Donata Campra; Robert Grützmann; Helga Rehder; Matthias Rothmund; Wolff Schmiegel; John P Neoptolemos; Detlef K Bartsch Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: Cristina R Ferrone; Douglas A Levine; Laura H Tang; Peter J Allen; William Jarnagin; Murray F Brennan; Kenneth Offit; Mark E Robson Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: David B Zhen; Kari G Rabe; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michael G Goggins; Ralph H Hruban; Michele L Cote; Robert R McWilliams; Nicholas J Roberts; Lisa A Cannon-Albright; Donghui Li; Kelsey Moyes; Richard J Wenstrup; Anne-Renee Hartman; Daniela Seminara; Alison P Klein; Gloria M Petersen Journal: Genet Med Date: 2014-11-20 Impact factor: 8.822
Authors: Talia Golan; Tal Sella; Eileen M O'Reilly; Matthew H G Katz; Ron Epelbaum; David P Kelsen; Ayelet Borgida; Hannah Maynard; Hedy Kindler; Eitan Friedmen; Milind Javle; Steven Gallinger Journal: Br J Cancer Date: 2017-02-09 Impact factor: 7.640
Authors: J Iqbal; A Ragone; J Lubinski; H T Lynch; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; E Friedman; M Llacuachaqui; S Ping; S A Narod Journal: Br J Cancer Date: 2012-10-25 Impact factor: 7.640
Authors: Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly Journal: Cancer Treat Rev Date: 2019-03-22 Impact factor: 12.111
Authors: Valentina Silvestri; Goska Leslie; Daniel R Barnes; Bjarni A Agnarsson; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Rosa B Barkardottir; Alicia Barroso; Daniel Barrowdale; Javier Benitez; Bernardo Bonanni; Ake Borg; Saundra S Buys; Trinidad Caldés; Maria A Caligo; Carlo Capalbo; Ian Campbell; Wendy K Chung; Kathleen B M Claes; Sarah V Colonna; Laura Cortesi; Fergus J Couch; Miguel de la Hoya; Orland Diez; Yuan Chun Ding; Susan Domchek; Douglas F Easton; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Lidia Feliubadalò; Lenka Foretova; Florentia Fostira; Lajos Géczi; Anne-Marie Gerdes; Gord Glendon; Andrew K Godwin; David E Goldgar; Eric Hahnen; Frans B L Hogervorst; John L Hopper; Peter J Hulick; Claudine Isaacs; Angel Izquierdo; Paul A James; Ramunas Janavicius; Uffe Birk Jensen; Esther M John; Vijai Joseph; Irene Konstantopoulou; Allison W Kurian; Ava Kwong; Elisabetta Landucci; Fabienne Lesueur; Jennifer T Loud; Eva Machackova; Phuong L Mai; Keivan Majidzadeh-A; Siranoush Manoukian; Marco Montagna; Lidia Moserle; Anna Marie Mulligan; Katherine L Nathanson; Heli Nevanlinna; Joanne Ngeow; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Ana Osorio; Laura Papi; Sue K Park; Inge Sokilde Pedersen; Pedro Perez-Segura; Annabeth H Petersen; Pedro Pinto; Berardino Porfirio; Miquel Angel Pujana; Paolo Radice; Johanna Rantala; Muhammad U Rashid; Barak Rosenzweig; Maria Rossing; Marta Santamariña; Rita K Schmutzler; Leigha Senter; Jacques Simard; Christian F Singer; Angela R Solano; Melissa C Southey; Linda Steele; Zoe Steinsnyder; Dominique Stoppa-Lyonnet; Yen Yen Tan; Manuel R Teixeira; Soo H Teo; Mary Beth Terry; Mads Thomassen; Amanda E Toland; Sara Torres-Esquius; Nadine Tung; Christi J van Asperen; Ana Vega; Alessandra Viel; Jeroen Vierstraete; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Sook-Yee Yoon; Kristin K Zorn; Lesley McGuffog; Michael T Parsons; Ute Hamann; Mark H Greene; Judy A Kirk; Susan L Neuhausen; Timothy R Rebbeck; Marc Tischkowitz; Georgia Chenevix-Trench; Antonis C Antoniou; Eitan Friedman; Laura Ottini Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777
Authors: Parisa Momtaz; Catherine A O'Connor; Joanne F Chou; Marinela Capanu; Wungki Park; Chaitanya Bandlamudi; Michael F Berger; David P Kelsen; Sarah P Suehnholz; Debyani Chakravarty; Kenneth H Yu; Anna M Varghese; Alice Zervoudakis; Jia Li; Geoffrey Y Ku; Jennifer S Park; Marina Shcherba; James J Harding; Zoe Goldberg; Ghassan K Abou-Alfa; Erin E Salo-Mullen; Zsofia K Stadler; Christine A Iacobuzio-Donahue; Eileen M O'Reilly Journal: Cancer Date: 2021-08-05 Impact factor: 6.921
Authors: Siddhartha Yadav; Pashtoon M Kasi; William R Bamlet; Thanh P Ho; Eric C Polley; Chunling Hu; Steven N Hart; Kari G Rabe; Nicholas J Boddicker; Rohan D Gnanaolivu; Kun Y Lee; Tricia H Lindstrom; Gloria M Petersen; Fergus J Couch; Robert R McWilliams Journal: Clin Cancer Res Date: 2020-10-07 Impact factor: 13.801